Top Story

Stegmann canal expander helps lower IOP in patients with primary open-angle glaucoma

August 24, 2016

The Stegmann canal expander, implanted during canaloplasty, lowered IOP and reduced complications in patients with primary open-angle glaucoma, according to a study.

The prospective, single-center noncomparative study included 22 eyes of 22 consecutive patients with medically uncontrolled primary open-angle glaucoma who underwent primary viscocanalostomy and implantation of the new canal expander. The expander was implanted into Schlemm’s canal, and patient follow-up time was at least 1 year.

Auven Therapeutics completes enrollment in phase 3 study of Seciera for dry eye

August 24, 2016
Auven Therapeutics completed enrollment in a phase 3 confirmatory study of Seciera for the treatment of dry eye disease, according to a press release. Seciera (OTX-101)…

Face transplant recipient continues successful recovery 1 year later

August 24, 2016
The recipient of the most extensive face transplant ever performed is experiencing a successful recovery at the 1-year anniversary of the surgery, according to NYU…

Zeiss reports revenue increase in first 9 months of fiscal year

August 24, 2016
Carl Zeiss Meditec reported a 6.7% increase in revenue in the first 9 months of its fiscal year, according to a press release. Revenue totaled 798.6 million…

Publication Exclusive: Surgeons detail steps for simple limbal epithelial transplantation

August 24, 2016
In 1964, Jose Barraquer described a surgical technique for limbal stem cell deficiency, or LSCD. The paramount finding of extensive LSCD is conjunctival transgression…
More News Headlines »
Clinical Science

En Face Spectral-Domain Optical Coherence Tomography for the Diagnosis and Evaluation of Polypoidal Choroidal Vasculopathy

Ophthalmic Surgery, Lasers and Imaging Retina, August 2016, Volume 47 Issue 8
To evaluate the diagnostic capability of en face spectral-domain optical coherence tomography (SD-OCT) in patients with…
More »

Imaging Modalities in Clinical Trials

This activity is supported by educational grants from Allergan, Inc.; Genentech, Inc.; and Regeneron Pharmaceuticals, Inc.

The advent of intravitreal therapies to treat retinal diseases has revolutionized the management of retinal pathology…
More »
Meeting News Coverage

VIDEO: Review finds no difference in anti-VEGF agents used for diabetic retinopathy

August 16, 2016
More »